Jodie Morrison

Jodie P.
Morrison is the founder of Morrison Advisory Consulting.
Current roles include Chief Executive Officer & Director at Q32 Bio, Inc. since 2024; President, Chief Executive Officer & Secretary at Q32 Bio Operations, Inc.; Director at Rectify Pharmaceuticals LLC; President, Secretary & Director at Q32 Bio Securities Corp.; Advisor at Atlas Venture Advisors, Inc. since 2021; and Advisor at Atlas Venture Life Science Advisors LLC since 2021.
Former positions include Chief Executive Officer & Director at Keryx Biopharmaceuticals, Inc. in 2018; President, Chief Executive Officer & Director at Tokai Pharmaceuticals, Inc. from 2013 to 2017; Chief Executive Officer & Director at Cadent Therapeutics, Inc. from 2019 to 2021; President & Chief Executive Officer at eGenesis, Inc. in 2017; Chairman at Ribon Therapeutics, Inc.; Director-Clinical Operations at Dyax Corp.
from 2012 to 2013; Independent Director at Rein Therapeutics, Inc. from 2017 to 2023; Independent Director at Akebia Therapeutics, Inc. from 2018 to 2020; Member Board Of Directors and Director at Eledon Pharmaceuticals, Inc. from 2013 to 2018; Independent Director at Verve Therapeutics, Inc. from 2024 to 2025; Principal at Diacrin, Inc. (Delaware); Principal at Curis, Inc.; and Chief Operating Officer at Syntimmune, Inc. in 2018.
Education includes undergraduate studies at Mount Holyoke College.